DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05071898

PORT

RecruitingPhase 1

Pharmacogenetics of Response to GLP1R Agonists

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

600

estimated

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥27

Primary endpoints

•First phase insulin secretion•Second phase insulin secretion•Glucose disappearance

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05071898
Org study IDHP00097563

Timeline

Milestones

Study first posted2021-10-08actual
Study start2022-04-11actual
Last update posted2025-07-01actual
Primary completion2026-11-30estimated
Study completion2027-12-31estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age89 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•BMI greater than or equal to 27 kg/m2
•Of Amish Descent

Exclusion criteria

•Woman of childbearing age who is sexually active
•History of diabetes (HbA1c > 6.5% or random glucose >200 mg/dL)
•Known allergy to semaglutide
•Medical issues, which in the judgment of the research physician or PIs might increase the risk associated with participation in the study
•eGFR < 60 mL/min/1.73 sq. m.
•Hematocrit < 35%
•TSH < 0.4 o4 > 5.5
•AST or ALT in excess of 2X the upper limit of normal
•Unable to discontinue a drug, vitamin, or nutritional supplement, which in the judgment of the research physician or PIs might alter the response to semaglutide
•Personal or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia, type 2

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
5
Weight & body composition
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Weight loss

Time frame:Assessed after completing 6 weeks of semaglutide therapy

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

5 endpoints
Primary/protocol endpoint/low confidence

First phase insulin secretion

Time frame:Measured both at baseline and after completing 6 weeks of semaglutide therapy

concentration, descriptive

Primary/protocol endpoint

Second phase insulin secretion

Time frame:Measured both at baseline and after completing 6 weeks of semaglutide therapy

concentration, descriptive

Primary/protocol endpoint/low confidence

Rate of glucose disappearance

Time frame:Measured both at baseline and after completing 6 weeks of semaglutide therapy

change from baseline, improvement

Other/protocol endpoint

Insulin sensitivity (Si)

Time frame:Measured both at baseline and after completing 6 weeks of semaglutide therapy

HOMA-IR (insulin sensitivity)

change from baseline, improvement

Other/protocol endpoint

Glucose effectiveness (Sg)

Time frame:Measured both at baseline and after completing 6 weeks of semaglutide therapy

change from baseline, improvement

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.